GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...

GSK’s fair value estimate has increased from £18.07 to £18.27, indicating a minor but notable shift in analysts’ outlook for ...

The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of ...

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

Analysts at Berenberg slightly raised their target price on drugmaker GSK from £16 to £16.60 per share on Tuesday after it hosted chief financial officer Julie Brown for the eighth session of its ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

AnaptysBio ( ($ANAB) ) has provided an update. On November 20, 2025, AnaptysBio filed a complaint in Delaware Chancery Court against TESARO, Inc.

GSK has escalated a dispute over rights to its cancer immunotherapy Jemperli, after its subsidiary Tesaro filed a complaint ...

GSK is investing £45m with the Fleming Initiative to launch six research programmes using cutting-edge AI to tackle ...